Editas Q3 Loss Narrows to $23.4M; Cash Runway Extended Into 2H 2028
EDIT sits 57% above its 52-week low of $1.66.
Summary
Editas reported a narrower Q3 loss of $23.4 million ($0.15 per share) on higher collaboration revenue and said $190.2 million in cash funds operations into the second half of 2028, past key EDIT-401 readouts.
Key Events · Earnings and Guidance · EDIT
-
Q3 Loss Narrows on Partner Revenue
Net loss was $23.4 million, or $0.15 per share, versus $25.1 million, or $0.28 per share, a year earlier. Collaboration and other R&D revenue rose to $10.4 million from $7.5 million, driven by clinical milestones achieved by a strategic partner.
-
Cash Runway Extended Into 2H 2028
Cash, cash equivalents and marketable securities totaled $190.2 million at September 30, 2026, up from $146.6 million at December 31, 2025. Management expects this to fund operations into the second half of 2028.
-
BMS Milestone Triggered by Second IND
A second IND/CTA was accepted for BMS-986527, a CD70 healthy-donor allogeneic CAR-T therapy, under the Bristol Myers Squibb collaboration, triggering a milestone payment to Editas.
-
EDIT-401 Dosing on Track for 2026
Australian HREC approval and TGA clinical trial notification are in hand for the Phase 1/2 Strive study in HeFH. Editas still expects to begin patient dosing this year and report initial safety and tolerability data in Q1 2027, with Part 1 topline in the second half of 2027.
Analysis · EDIT · Life Sciences
The quarter improved rather than deteriorated: net loss fell to $23.4 million ($0.15 per share) from $25.1 million ($0.28 per share) a year earlier, and collaboration revenue nearly doubled to $10.4 million on a partner milestone. For a clinical-stage gene editor, the balance sheet matters most, and $190.2 million in cash and securities now funds operations into the second half of 2028 — past the initial Strive safety data expected in Q1 2027 and the Part 1 topline in the second half of 2027. That removes the near-term need to lean on the $150M ATM launched in August, which followed the May suspension of the prior program. Cost is the offset: R&D rose $1.4 million and G&A $1.2 million year over year, partly from intellectual property defense, so the runway extension comes from the stronger cash position rather than from shrinking the burn.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EDIT was trading at $2.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $394.7M. The 52-week trading range was $1.66 to $3.94. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.